Daewoong Pharmaceutical’s domestically developed diabetes treatment “Enblo” is entering eight major markets in the Middle East and Africa. Daewoong Pharmaceutical announced on the 2nd that it had signed an export supply contract for Enblo worth KRW 145.2 billion with Swiss pharmaceutical company Acino. This is the largest contract since the global commercialization of Enblo began. Enblo is scheduled to be launched sequentially, starting with Saudi Arabia in the first half (January–June) of 2027, followed by the United Arab Emirates (UAE), Qatar and others.

Enblo is a type 2 diabetes treatment in the “SGLT-2 inhibitor” class that lowers blood sugar by preventing the reabsorption of glucose in the kidneys. This is the first time that a domestically developed SGLT-2 inhibitor diabetes treatment has entered the Middle East and Africa markets. According to the International Diabetes Federation (IDF), the Middle East and Africa have the highest diabetes prevalence in the world, with 1 in 6 adults suffering from the disease.

Popular News